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Objective: An increased cardiovascular mortality and morbidity has been widely reported in
patients with atrial fibrillation (AF). In this study, a subanalysis of the AntiThrombotic Agents
Atrial Fibrillation (ATA-AF) is performed with the aim to evaluate estimated glomerular filtration
rate (eGFR) as an independent prognostic marker of cardiovascular mortality and morbidity in
patients with AF.
Methods and Results: The ATA-AF study enrolled 7148 patients with AF, in 360 Italian centers.
The eGFR was calculated from data reported in patient notes or hospital database. This post-
hoc analysis included 1097 AF patients with eGFR data available and 1-year clinical follow-up.
The endpoint was assessed as cardiovascular mortality and/or hospital admission for cardiovas-
cular causes at follow-up. Patients were also divided in two groups according to the eGFR (<60
and ≥60 mL/min/1.73 m2). The Kaplan-Meyer curve for the mentioned endpoint showed a
higher endpoint incidence in the group of patient with eGFR below 60 mL/min/1.73 m2
(P < 0.001). Using multivariate analysis (Cox regression), a trend toward a higher rate of occur-
rence of the primary endpoint was observed for eGFR below 60 mL/min/1.73 m2 without
reaching the conventional level of statistical significance (hazard ratio [HR] 1.40; 95% confi-
dence interval [CI] 0.99-1.99; P = 0.0572). When eGFR was included in the analysis as continu-
ous variable a significant correlation was observed with the combined endpoint at the Cox
regression (HR 0.99, 95% CI 0.98-0.99, P = 0.04).
Conclusion: The result of this post-hoc analysis indicates that an impaired eGFR is indepen-
dently associated with worse prognosis among patients with AF.
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1 | INTRODUCTION
An increased cardiovascular mortality and morbidity not related to
stroke, including occurrence of ischemic heart disease, congestive
heart failure, and cardiovascular hospitalization, has been widely
reported in patients with atrial fibrillation (AF),1 albeit overshadowed
by the risk of thromboembolic events.
Likewise, few studies2,3 looking at the clinical markers capable of
stratifying the long-term prognosis in patients with AF have applied
the risk stratification used to determine the CHADS score, although
with limited success.
†See Appendix S1 for a complete list of participating Centers and Investigators.
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In contrast, chronic kidney disease (CKD), which had been not
included in the algorithm for thromboembolic risk stratification in
patients with AF, is a well-known risk factor for mortality, cardiovas-
cular events, and hospitalization in the general population.4–6
In large population from the Danish national registry, Olesen
et al7 reported that CKD is independently associated with stroke and
systemic embolism in patients with AF.
More recently, an impaired glomerular filtration rate (GFR) com-
bined with a high CHADS score has been shown to be an effective
predictor of cardiovascular event and mortality in patients with AF.8
The AntiThrombotic Agents Atrial Fibrillation (ATA-AF) study9 is a
multicenter observational study that assessed the differences in clini-
cal profile and treatment strategies between patients with AF,
referred to cardiology and internal medicine units.
A subanalysis on the ATA-AF population is presented with the aim
to evaluate the association between estimated glomerular filtration rate
(eGFR) and cardiovascular mortality and morbidity in patients with AF.
2 | METHODS
The ATA-AF study has been described somewhere else9; briefly from
May to July 2010, 7148 patients with AF, of which 4845 with a non-
valvular form, were enrolled in 360 Italian centers. A substudy was
run in 64 centers that followed-up a total of 1368 patients for 1 year;
among these 1097 patients had data on eGFR and were included in
this subanalysis. The clinical and therapeutic management was
assessed according to the department of admission, either medicine
or cardiology. The only exclusion criterion was AF after acute coro-
nary syndrome or cardiothoracic surgery (within 1 week from symp-
tom onset or surgery).
Information regarding occurrence of major cardiovascular events
requiring hospitalization or mortality were collected at follow-up visits
or through phone calls to the patients and their relatives.
All patients gave written informed consent. The study protocol
conforms to the ethical guidelines of the Declaration of Helsinki as
reflected in a priori approval by the institution’s human research com-
mittee. The eGFR was calculated from data reported in patient notes
or hospital database, according to the CKD-EPI Creatinine Equation.
The clinical outcome was assessed as composite endpoint of car-
diovascular mortality and/or hospital admission for cardiovascular
causes at 1-year follow-up. Occurrence of thromboembolic events,
including ischemic and hemorrhagic stroke, pulmonary, or peripheral
embolism, was assessed as a secondary endpoint.
In our analysis, an eGFR of 60 mL/min/1.73 m2, was used as cutoff
point to assign patients into two groups; equal and above (preserved
eGFR), or below the cutoff point (impaired eGFR). In order to evaluate
the effect of eGFR on the clinical outcome we also considered eGFR
both as a continuous variable and in three groups <30 mL/min/1.73
m2, from 30 to 59 mL/min/1.73 m2, and ≥60 mL/min/1.73 m2.
2.1 | Statistical analysis
Continuous variable are expressed as mean and SDs, and were com-
pared by Mann-Whitney U test. Categorical variables are reported as
number and percentages, and were compared by χ2 test. A multivariable
analysis (Cox regression) was used to determine the independent pre-
dictors of the combined endpoint of cardiovascular mortality and/or
hospitalization for cardiovascular causes at 1 year follow-up, using the
variables that were statistically significant at univariate analysis (eGFR
among these), and gender and age, even though not significant. Three
models were performed, the first with eGFR in two classes (<60;
≥60 mL/min/1.73 m2), the second with eGFR in three classes (<30;
30-59; ≥60 mL/min/1.73 m2, with the latter as reference group), and
the last with eGFR as continuous. Kaplan-Meier curves for the com-
bined outcome were produced by eGFR (preserved vs impaired), and
compared by log-rank test. For the eGFR the linearity of the risk was
evaluated by restricted cubic splines. A P value <0.05 was considered
statistically significant. All analyses were performed with SAS system
software (SAS Institute Inc, Cary, NC, USA), version 9.2.
3 | RESULTS
3.1 | Baseline characteristics
In the ATA-AF study population, data on GFR were available in 5681
of 7148 enrolled patients (79.5%). Baseline clinical characteristics of
patients with and without data on eGFR are shown in Supporting
Information Table S1. Patients with data on GFR were older and had a
higher CHADS2 score and a lower body mass index (BMI). Cognitive
deficit, dementia, heart failure, ischemic cardiomyopathy, diabetes,
transient ischemic attack (TIA), cancer, and anemia were significantly
higher among patients with data on eGFR.
Among the 5681 patients with data on GFR, 1-year clinical
follow-up was available for 1097 patients in 67 of the 360 centers
participating in the substudy.
The clinical characteristics of the patients with and without
follow-up are reported and compared in Table S2. Patients with an
eGFR and 1-year clinical follow-up were younger, more likely to be
admitted in a cardiology department, and had a lower CHADS2 and
CHA2D2SVasc score. Prevalence of cognitive deficit and dementia,
stroke, peripheral vascular disease, cancer, anemia, and chronic
obstructive pulmonary disease (COPD) was significantly lower among
patients with eGFR and clinical follow-up. Persistent AF was more
prevalent among patients with follow-up while paroxysmal and per-
manent AF were more prevalent among patients without. Finally,
patients with clinical follow-up were more likely to be on oral antico-
agulants (OAC) and propafenone, and less on ASA.
Among the 1097 patients with eGFR and 1-year follow-up data,
459 (42%) had eGFR <60 mL/min/1.73 m2, while 638 (58%) had
eGFR ≥60 mL/min/1.73 m2. A comparison between the baseline char-
acteristics of patients with 1-year follow-up divided in the two groups
according to eGFR is reported in Table 1. Patients with an eGFR
<60 mL/min/1.73 m2 were older, less likely to be admitted in a cardi-
ology department, predominantly female and not smokers, and had a
higher CHADS2 and CHA2D2SVasc score. In this subgroup, the preva-
lence of cognitive deficit, heart failure, hypertension, diabetes and
TIA, peripheral vascular disease, cancer, anemia, and COPD was signif-
icantly higher.
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TABLE 1 Baseline characteristics and therapy at enrollment of the patients with 1-year follow up divided in the two groups with eGFR below or
equal and above 60 mL/min/1.73 m2
eGFR < 60 eGFR ≥ 60 P-value
Number of patients, n (%) 459 (41.8) 638 (58.2)
Cardiology department of admission, n (%) 254 (55.3) 415 (65.1) 0.001
Male, n (%) 199 (43.4) 387 (60.7) <0.0001
Age (SD) 79 (8.0) 71 (11.0) <0.0001
BMI (SD) 26.7 (4.2) 27.0 (4.5) 0.28
Smoke, n (%) 14 (3.1) 57 (8.9) <0.0001
Hypercholesterolemia, n (%) 138 (30.1) 196 (30.7) 0.82
Cognitive deficit, n (%) 29 (6.3) 19 (3.0) 0.008
Dementia, n (%) 10 (2.2) 10 (1.6) 0.46
Heart failure, n (%) 180 (39.2) 146 (22.9) <0.0001
Diabetes, n (%) 142 (30.9) 123 (19.3) <0.0001
Hypertension, n (%) 375 (81.7) 457 (71.6) 0.0001
TIA, n (%) 46 (10.0) 33 (5.2) 0.002
Stroke, n (%) 35 (7.6) 40 (6.3) 0.38
Ischemic CMP, n (%) 112 (24.4) 105 (16.5) 0.001
Dilated CMP, n (%) 69 (15.0) 65 (10.2) 0.02
Hypertensive CMP, n (%) 227 (49.5) 277 (43.4) 0.048
Hypertrophic CMP (%) 15 (3.3) 9 (1.4) 0.04
Other CMP, n (%) 34 (7.4) 39 (6.1) 0.40
Valvular CMP, n (%) 153 (33.3) 170 (26.7) 0.02
CHADS2 score (SD) 2.5 (1.3) 1.7 (1.2) <0.0001
CHA2D2vasc score (SD) 4.3 (1.5) 3.0 (1.7) <0.0001
Prior PM, n (%) 61 (13.3) 48 (7.5) 0.002
Prior ICD, n (%) 18 (3.9) 17 (2.7) 0.24
Hyperthyroidism, n (%) 14 (3.1) 41 (6.4) 0.01
Hypothyroidism, n (%) 46 (10.0) 35 (5.5) 0.005
Peripheral vascular disease, n (%) 60 (13.1) 33 (5.2) <0.0001
Renal failure, n (%) 186 (40.5) 16 (2.5) <0.0001
COPD, n (%) 91 (19.8) 97 (15.2) 0.045
Sleep apnea, n (%) 7 (1.5) 6 (0.9) 0.38
Anemia, n (%) 85 (18.5) 51 (8.0) <0.0001
Cancer, n (%) 52 (11.3) 39 (6.1) 0.002
Type of AF <0.0001
Paroxysmal, n (%) 79 (17.2) 165 (25.8)
Permanent, n (%) 274 (59.7) 254 (39.8)
Persistent, n (%) 89 (19.4) 200 (31.4)
Other AF, n (%) 17 (3.7) 19 (3.0)
EFa % (SD) 50.0 (12.0) 53.2 (11.2) <0.0001
Hemoglobin g/dL (SD) 12.4 (1.8) 13.5 (1.9) <0.0001
Creatinine mg/dL (SD) 1.5 (0.8) 0.9 (0.2) <0.0001
GFR-EPI mL/min/1.73 m2 (SD) 42.6 (12.5) 79.3 (13.0) <0.0001
Therapy prescribed at enrollment
OAC, n (%) 315 (68.6) 416 (65.2) 0.24
ASA, n (%) 108 (23.5) 154 (24.1) 0.82
Anti-arrhythmic therapy
Amiodarone, n (%) 72 (15.7) 118 (18.5) 0.23
Propafenone, n (%) 11 (2.4) 42 (6.6) 0.001
Sotalol, n (%) 3 (0.7) 26 (4.1) 0.0005
Flecainide, n (%) 11 (2.4) 32 (5.0) 0.03
Beta-blockers, n (%) 228 (49.7) 289 (45.3) 0.15
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Patients with eGFR <60 mL/min/1.73 m2 had more likely perma-
nent AF while those with eGFR ≥60 mL/min/1.73 m2 a paroxysmal
and persistent form. The latter were in a larger proportion on anti-
arrhythmic therapy with class Ic drugs. Finally, no significant differ-
ences between the groups were detected on the proportion of
patients on OAC and antiplatelet.
3.2 | Clinical outcome
Table 2 displays the major causes for hospital admission and mortality;
death for cardiovascular causes was significantly higher (P < 0.0001)
in the group with eGFR <60 mL/min/1.73 m2. Hospital admissions
were comparable between the two groups.
At 1-year follow-up, 210 patients (19%) presented a major cardiovas-
cular event (death or hospital admission) and at univariate analysis, a sta-
tistically significant higher occurrence of the composite endpoint was
observed in the group with eGFR below 60 (χ2 = 9.8, P = 0.002) (Table 2).
Accordingly, the Kaplan-Meyer curve for the composite endpoint
of cardiovascular mortality and/or hospitalization for cardiovascular
causes at 1-year follow-up showed a higher incidence of new events
in the group of patients with eGFR below 60 mL/min/1.73 m2 (P-
value long-rank <0.001) (Figure 1).
Over the 1-year follow-up, 20 thromboembolic events have been
reported including fatal and nonfatal cases. Sixteen occurred in the
group with eGFR <60 mL/min/1.73 m2 and four in the group with
eGFR ≥60 mL/min/1.73 m2 (P = 0.0005).
3.3 | Multivariable analyses
3.3.1 | Model with eGFR divided in two groups (<60 or
≥60 mL/min/1.73 m2)
At multivariate analysis only the type of center (internal medicine vs
cardiology, adjusted hazard ratio [HR] 1.83, 95% confidence interval
[CI] 1.33-2.52), the presence of congestive heart failure (adjusted HR
1.52, 95% CI 1.10-2.09), hypothyroidism (adjusted HR 1.75, 95% CI
1.12-2.74), and the presence of previous implantable cardiac defibril-
lator (ICD) (adjusted HR 2.24 95% CI 1.24-4.06) were significantly
associated with the combined endpoint of cardiovascular mortality
and/or hospitalization for cardiovascular causes at 1-year follow-up;
the presence of an impaired renal function (eGFR below 60 mL/
min/1.73 m2) showed a trend toward a positive association with a
higher rate of occurrence of the primary outcome measure, but the
conventional level of statistical significance was not reached (HR 1.40,
95% CI 0.99-1.99, P = 0.0572) (Table 3A).
3.3.2 | Model with eGFR divided in three groups (<30,
30-59, ≥60 mL/min/1.73 m2)
In this analysis, patients were divided in three groups according to the
eGFR (<30, 30-59, ≥60 mL/min/1.73 m2) and assessed on the com-
bined outcome (mortality/hospital admissions for CV causes). The
results of the adjusted analysis including the other clinical variables
are shown in Table 3B. The group with preserved eGFR (≥60 mL/
min/1.73 m2) was used as the comparison group. A statistically signifi-
cant difference was detected between the group with eGFR <30 mL/
TABLE 1 (Continued)
eGFR < 60 eGFR ≥ 60 P-value
ACE-inhibitors, n (%) 178 (38.8) 257 (40.3) 0.62
Sartans, n (%) 134 (29.2) 163 (25.6) 0.18
Diuretics, n (%) 336 (73.2) 328 (51.4) <0.0001
Anti-aldosterone, n (%) 66 (14.4) 93 (14.6) 0.93
Oral hypoglycaemic, n (%) 63 (13.7) 77 (12.1) 0.42
Insulin, n (%) 43 (9.4) 22 (3.5) <0.0001
Digoxin, n (%) 114 (24.8) 141 (22.1) 0.29
Abbreviations: ACE, angiotensin converting enzyme; AF, atrial fibrillation; ASA, acetylsalicylic acid BMI, body mass index; CHADs2, congestive heart failure,
Hypertension, Age (>=65=1point, >=75=2points), Diabetes and Stroke/TIA (2 points); CMP, (documented) cardiomyopathy; COPD, chronic obstructive pul-
monary disease; EF, ejection fraction; EPI, epidemiology; eGFR, estimated Glomerular Filtration Rate; ICD, implantable cardiac defibrillator; OAC, oral anti-
coagulants; PM, pacemaker; TIA, transient ischemic attack.
a EF available for 856 patients.
TABLE 2 Major causes for hospital admission and mortalitya
eGFR < 60 (n = 459) eGFR ≥ 60 (n = 638) P-value
Number of death, n (%) 87 (19.0) 39 (6.1) <0.001
Deaths for CV causes, n (%) 44 (9.6) 12 (1.9) <0.0001
Deaths non-CV causes, n (%) 21 (4.6) 13 (2.0) 0.02
Not known, n (%) 22 (4.8) 14 (2.2) 0.02
Hospital admissions, n (%) 123 (26.8) 136 (21.3) 0.035
Hospital admission CV causes, n (%) 81 (17.7) 95 (14.9) 0.22
Hospital admission non-CV causes, n (%) 51 (11.1) 46 (7.2) 0.02
Deaths for CV causes/hospital admission CV causes,
n (%)
108 (23.5) 102 (16.0) 0.002
Abbreviations: CV, cardiovascular; eGFR, estimated Glomerular Filtration Rate.
a 1097 patients with 1 year-follow-up available.
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min/1.73 m2 and ≥60 mL/min/1.73 m2 (HR 2.62, 95% CI 1.43, 4.79,
P = 0.0017). Conversely, no statistically significant difference was
detected between the group with eGFR 30-59 mL/min/1.73 m2 and
≥60 mL/min/1.73 m2 (HR 1.37, 95% CI 0.96-1.95, P = 0.0825).
3.3.3 | Model with eGFR as continuous variable
In the third analysis, the eGFR was considered as a continuous vari-
able. Univariate Cox regression assessing the association between the
composite endpoint (mortality/hospital admission for CV causes) and
the eGFR showed a significant inverse correlation (HR 0.987, 95% CI
0.981-0.993, P < 0.0001). In the adjusted analysis that included the
other clinical variables the association between level of eGFR and clin-
ical endpoints was also statistically significant (HR 0.99, 95% CI
0.98-0.99, P = 0.04) (Table 3C).
4 | DISCUSSION
The results of our post-hoc analysis performed on the data of the
ATA-AF study shows that eGFR is independently associated with
worse prognosis in patients with AF. An impaired eGFR heralds a
higher risk for cardiovascular morbidity and mortality among patients
with AF.
The association between mortality and AF has recently become
more apparent; three epidemiological studies10–12 from different
countries analyzing death certificates have consistently described a
relevant association between mortality and AF. In addition, several
cohort studies in patients with AF have shown an independent associ-
ation with mortality with a relative risk of death reported ranging from
1.5 to 2.5.1 A recent meta-analysis, that included 104 studies and
587 867 patients, reported an absolute risk in cardiovascular mortality
associated to AF of 2.6 events/1000 cases per year. In the same anal-
ysis, the pooled relative risk of congestive heart failure and ischemic
heart events was reported around 4.99 (95% CI 3.04-8.22) and 1.61
(95% CI 1.38-1.87), respectively.1
Although the strength of the evidence cannot support direct cau-
sality, as for stroke, it identifies an increased cardiovascular mortality
and morbidity in patients with AF, independent from thromboembolic
events. This mortality risk needs to be adequately evaluated and
addressed by clinicians.
Consequently, the identification of clinical markers capable of
stratifying the long-term prognosis in patients with AF may become
clinically relevant. However, only a few studies have evaluated the
possible predictors of death and cardiovascular events in patients with
AF. Most of these studies applied the thromboembolic risk stratifica-
tion used to calculate the CHADS2 score with limited results.
Nakagawa et al8 in a cohort of 387 patients with nonvalvular AF
followed-up for 5.6 years, has found that a decrease in the eGFR
below 60 mL/min/1.73 m2 combined with a CHADS2 score greater
than 2, were robust forecasters of cardiovascular events and mortal-
ity.8 Previously, Guo et al13 had shown that in patients with AF, the
deterioration in renal function increases the risk of death. Lin et al14
has shown that in the presence of a low CHA2D2Svasc between 1 and
2, an impaired renal function (<60 mL/min/1.73 m2) identifies patients
at higher risk for cardiovascular morbidity and ischemic events.
More recently, Kodani et al15 in the post-hoc analysis of the J-
Rhythm registry have reported that even a moderate renal impairment
(CrCl 30-49.9 mL/min) carries increased risk for all-cause and cardio-
vascular mortality in patients with AF. It is worth mentioning that the
authors used creatinine clearance for the assessment of the renal
FIGURE 1 Kaplan-Meyer curve showing free-events survival on the composite endpoint of cardiovascular mortality and/or hospitalization for
cardiovascular causes at 1-year follow-up in the group the two groups with eGFR < or ≥60 mL/min/1.73 m2 (P-value long-rank < 0.001). eGFR,
estimated glomerular filtration rate
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function. It is well known that the creatinine clearance tends to over-
estimate the eGFR, which may partially explain the difference in sur-
vival they detected even for mild renal insufficiency. Conversely, in
our analysis a worse clinical outcome is significantly associated with a
severe impairment in eGFR (<30 mL/min/1.73 m2). In addition, eGFR
was calculated in our study according to the CKD-EPI Creatinine
Equation, which has been shown by Boriani et al16 in the data of
EORP-AF registry to have better precision than the other available
formulas for eGFR calculation in identifying class of AF patients with
renal impairment at increased risk of CVE.
Of note our ancillary analysis of the ATA-AF registry shows that
an eGFR <60 mL/min/1.73 m2 is associated with a higher rate of
occurrence of CV mortality and hospitalization, but, after adjusted
analysis, this association was not confirmed. These results are in line
with the findings by Banerjee et al,17 in the Loire Valley AF project;
the authors reported that eGFR as a categorical variable was an inde-
pendent predictor of CVE but it lost its predictability when adjustment
for other confounding variables. It is worth mentioning that in the
Loire Valley AF project the eGFR was calculated according to the
MDRD (modification of diet in renal disease) equation.
It has been clearly demonstrated that CKD and AF share the same
pathophysiological mechanisms.18 For instance, Watanabe et al19 in a
community-based prospective study including 231 818 subjects,
reported a bidirectional risk between patients with CKD and
AF. Specifically, the authors reported a 77% increase in the risk of
developing CKD in patients with AF. Hence, it may be hypothesized
that renal impairment can act in conferring poor prognosis in patients
with AF as progressive eGFR deterioration that fails to be detected as
dichotomous discriminator.
The bidirectional link between AF and renal function is further
confirmed by studies conducted in patients who underwent catheter
ablation; evidence from a recent meta-analysis showed a higher
TABLE 3 Multivariable analyses on the combined end-point
cardiovascular mortality and/or hospitalization for cardiovascular
causes
HR 95% CI
(A) Model with eGFR divided in two groups (<60, ≥60 mL/min/1.73 m2)
Internal medicine vs cardiology admission 1.83 1.33-2.52
Female vs male 0.89 0.65-1.22
Age 0.99 0.97-1.01
DBP 0.99 0.97-1.00
Fall 1.91 0.96-3.81
Heart failure 1.52 1.10-2.09
Diabetes 1.28 0.95-1.74
Ischemic CM 1.27 0.92-1.77
Dilated CM 0.83 0.53-1.29
Smoke 0.51 0.24-1.11
Prior ICD 2.24 1.24-4.06
Hypothyroidism 1.75 1.12-2.74
Peripheral vascular disease 1.01 0.65-1.59
Renal failure 0.88 0.58-1.32
COPD 1.24 0.88-1.76
Anemia 0.98 0.62-1.54
Permanent/other/not detectable AF vs
paroxysmal AF
1.21 0.83-1.78
Persistent AF vs paroxysmal AF 1.19 0.76-1.87
Hemoglobin<12 g/dL 0.87 0.61-1.25
eGFR<60 mL/min/1.73 m2 1.40 0.99-1.99
(B) Model with eGFR divided in three groups (<30, 30-59, ≥60 mL/
min/1.73 m2)
Internal medicine vs cardiology admission 1.84 1.39-2.54
Female vs male 0.86 0.63-1.78
Age 0.99 0.97-1.00
DBP 0.99 0.97-1.00
Fall 2.02 1.01-4.02
Heart failure 1.50 1.08-2.09
Diabetes 1.28 0.94-1.73
Ischemic CM 1.22 0.87-1.69
Dilated CM 0.83 0.53-1.30
Smoker 0.49 0.23-1.08
Prior ICD 2.24 1.24-4.05
Hypothyroidism 1.74 1.11-2.72
Peripheral vascular disease 0.95 0.60-1.49
Renal failure 0.70 0.44-1.18
COPD 1.29 0.90-1.83
Anemia 0.91 0.57-1.45
Permanent/other/not detectable AF vs
paroxysmal AF
1.20 0.81-1.76
Persistent AF vs paroxysmal AF 1.19 0.76-1.87
Hemoglobin <12 g/dL 1.26 0.89-1.78
eGFR <30 mL/min/1.73 m2 2.62 1.43-4.79
eGFR 30-59 mL/min/1.73 m2 1.36 0.96-1.95
(C) Model with eGFR as continuous variable
Internal medicine vs cardiology admission 1.871 1.35-2.57
Female vs male 0.84 0.62-1.15
Age 0.98 0.96-1.00
DBP 0.98 0.97-1.00
Fall 2.12 1.06-4.25
TABLE 3 (Continued)
HR 95% CI
Heart failure 1.51 1.09-2.09
Diabetes 1.27 0.93-1.72
Ischemic CM 1.26 0.91-1.75
Dilated CM 0.81 0.51-1.26
Smoker 0.49 0.23-1.08
Prior ICD 2.15 1.19-3.90
Hypothyroidism 1.77 1.13-2.76
Peripheral vascular disease 0.98 0.63-1.55
Renal failure 0.74 0.48-1.15
COPD 1.26 0.89-1.79
Anemia 0.93 0.59-1.48
Permanent/other/not detectable AF vs
paroxysmal AF
1.86 0.8-1.74
Persistent AF vs paroxysmal AF 1.16 0.74-1.82
Hemoglobin<12 g/dL 1.25 0.88-1.77
eGFR 0.98 0.97-0.99
Abbreviations: AF, atrial fibrillation; CI, confidence interval; CM, (docu-
mented) cardiomyopathy; COPD, chronic obstructive pulmonary disease;
DBP, diastolic blood pressure; eGFR, estimated Glomerular Filtration Rate;
HR, hazard ratio; ICD, implantable cardiac defibrillator.
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incidence of AF recurrence after catheter ablation in patients with
CKD.20 In addition, more recently, a decline of eGFR has been shown
to be associated with episodes of AF recurrence after ablation.21 An
improvement in eGFR has been detected in patients with mild and
moderate renal impairment who were free of arrhythmia recurrence
after catheter ablation.22 Conversely, patients with AF and normal
renal function or mild renal dysfunctions treated medically experience
a decline in eGFR that is associated with increased thromboembolic
events and mortality.23
In support of this finding, our results show a significant associa-
tion between eGFR levels and the primary combined endpoint of the
analysis.
Finally, our analysis detected a significantly higher incidence of
thromboembolic events in patients with an impaired renal function.
This finding is in line with recent evidences that suggest impaired
renal function as a potential predictor of thromboembolic events.24
4.1 | Limitations
The main limitation of this study is that it represents a post-hoc analy-
sis of a study originally designed with a different aim. Furthermore,
only a small subset of the ATA-AF population had data on eGFR and
1-year follow-up and could be included in the analysis. Finally, our
results are limited at 1-year follow-up and do not provide long-term
follow-up.
5 | CONCLUSION
The result of this post-hoc analysis indicates that an impaired eGFR is
independently associated with a worse prognosis among patients
with AF.
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